The global pediatric cancer biomarkers market size was valued at USD 971.01 million in 2025 and is projected to grow from USD 1040.92 million in 2026 to USD 1815.41 million by 2034 at a CAGR of 7.2% during the forecast period 2026-2034.
A biomarker is a biological molecule found in blood, tissues, and other bodily fluids that serves as an indicator of a disease or condition. With the rising prevalence of pediatric carcinos globally, there has been a notable increase in demand for the development of pediatric cancer biomarkers.
Moreover, ongoing innovations in molecular research aimed at the early detection of carcinos in children are significantly driving the market growth. For example, in March 2024, scientists at the University of California, San Francisco, discovered a universal and critical biomarker for neuroblastoma, which could also become a promising target for new treatments.
Artificial intelligence (AI) is transforming pediatric cancer research by analyzing complex clinical trial data and predicting outcomes. AI's ability to manage large datasets enhances clinical management and diagnosis, aiding in identifying genetic mutations in tumors.
Early screening and diagnosis of pediatric cancer significantly improve survival rates and quality of life. Biomarkers play a pivotal role in enabling early detection, allowing healthcare professionals to choose optimal treatments during the initial stages.
For instance, in January 2024, Cure reported that biomarkers could predict heart problems in childhood cancer survivors, showcasing their potential in improving early diagnosis and post-treatment care.
Thus, early identification not only enhances treatment outcomes but also reduces the overall cost and financial burden associated with carcinos care.
Download Free Sample Report To learn more about this report,
The rising demand for non-invasive diagnostic techniques significantly drives the adoption of liquid biopsies in the global pediatric cancer biomarkers industry. Unlike traditional tissue biopsies, liquid biopsies rely on analyzing genetic biomarkers in body fluids, eliminating the need for invasive procedures. This innovation not only enhances patient comfort but also reduces overall medical costs compared to conventional biopsy methods.
Furthermore, liquid biopsies enable efficient early carcinos detection, real-time monitoring of therapeutic efficacy, and identification of therapeutic targets, making them invaluable for personalized treatment and diagnosis planning.
The increasing global burden of pediatric cancer is another key driver of market growth. The demand for accurate diagnosis and timely screening has surged as awareness about pediatric carcinos rises. While high-income countries benefit from advanced treatments and higher survival rates, low- and middle-income nations often face challenges such as limited access to diagnostic tools and care facilities.
Environmental factors, genetic predispositions, and lifestyle changes are contributing to a growing incidence of pediatric cancers, including brain cancers, leukemia, lymphomas, and solid tumors.
The high cost associated with pediatric cancer biomarkers is a significant market restraint. This is primarily due to the extensive clinical research required for their development, validation, and adherence to stringent regulatory standards. Moreover, advanced technologies, such as precision medicine tailored to the genetic profiles of individual patients, further escalate the cost of biomarkers. This limits their commercialization to patients who can afford such specialized diagnostics, creating a barrier to widespread adoption.
The integration of precision medicine into pediatric cancer treatment presents a significant opportunity for market growth. Precision medicine enhances therapeutic efficacy by targeting specific biomarkers or genetic profiles, offering tailored solutions for individual patients.
As research continues to advance, combining pediatric treatment protocols with precision medicine has shown promising results in improving survival rates and clinical responses. This creates immense potential for the expansion of pediatric cancer biomarkers in global healthcare.
Request Customizationto receive a tailored report.
Leukemia segment dominates the market with the highest market revenue due to its high prevalence among children. According to the Children's Hospital of Philadelphia, approximately 4,000 children are diagnosed with cancer annually in the U.S., with one-third of these cases being leukemia. This growing incidence drives the demand for biomarkers to enable early detection and monitor carcinos progression effectively, aiding in timely treatment and diagnosis.
CD19, CD20, CD22 segment dominates the market with the highest market revenue due to their critical role in advanced carcinos therapies. CD19, in particular, is a pivotal target for CAR-T cell therapies, such as axicabtagene ciloleucel, used in treating refractory or relapsed B-cell lymphoma and leukemia. These biomarkers enable precise, targeted treatments that improve outcomes for pediatric patients.
Hospitals dominate the global market as they are the primary centers for cancer diagnosis and treatment. With specialized pediatric oncology departments, hospitals offer advanced diagnostic tools, trained staff, and state-of-the-art facilities, enabling comprehensive care. Moreover, many clinical research studies on biomarkers are conducted in hospital settings, further driving their adoption. This infrastructure allows hospitals to cater to a large pediatric population, ensuring accurate diagnostics and personalized treatment plans, making them a cornerstone of the market.
Speak to an Analystto discuss market opportunities.
North America leads the global market, driven by significant investments in childhood cancer initiatives. Organizations like the American Cancer Society Cancer Action Network (ACS CAN) are advocating for substantial funding to improve outcomes for children with carcinos.
These investments aim to enhance research, improve treatment options, and support childhood cancer survivors, strengthening North America’s market dominance.
The Asia-Pacific region is the fastest-growing market, fueled by the rising incidence of pediatric cancer in countries like India and China. Improved healthcare infrastructure and supportive government initiatives are driving this growth. In India, public-private partnerships under the National Health Mission have significantly strengthened healthcare policies, expanding access to diagnostics and treatment.
Moreover, increased awareness and investments in healthcare technologies are further boosting the adoption of cancer biomarkers in this region. This rapid growth positions Asia-Pacific as a critical player in the global market.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Associate
Mitiksha Koul is a Research Associate with 2 years of experience in market research. She focuses on analyzing industry trends, competitive landscapes, and growth opportunities to support strategic decision-making. Mitiksha’s strong analytical skills and research expertise enable her to deliver actionable insights that help businesses adapt to evolving market dynamics and achieve sustainable growth.
We are featured on:
sales@straitsresearch.com